“We started the year strong. At a consolidated level, YoY revenue grew 23 percent, supported by robust growth in both
“Our financial performance this quarter included the impact of annual increases in personnel costs and higher input and freight costs, due to pandemic and geopolitical disruptions to global supply chains.
“All of our three companies are poised for the next phase of strong and sustainable growth that has been put to the test during the two years of the Covid-19 pandemic,” said Biocon and Biocon Biologics Executive
Sales of Glargine in the US and key biosimilars in emerging markets were the main drivers for
“Our strategic alliance with Serum Institute Life Sciences for vaccines and the acquisition of Viatris’s global biosimilar business is on track for closure in the second half of this calendar year.”
Reduction of rice, grain-sown area worrying: Bank of Baroda
Oppo Pad Air review: sleek and stylish but little power